Doxylamine/Pyridoxine (Xonvea®)

Assessment Status Rapid review complete
Drug Doxylamine/pyridoxine
Brand Xonvea®
Indication For the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Assessment Process
Rapid review commissioned 23/07/2019
Rapid review completed 15/08/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Xonvea®) not be considered for reimbursement at the submitted price*

* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.